3 New Papers: Low-Cal Diet Reverses T2D, TV Watching Raises COPD Risk, Haptic Device Beats Insomnia in a Week

3 New Papers: Low-Cal Diet Reverses T2D, TV Watching Raises COPD Risk, Haptic Device Beats Insomnia in a Week

This morning's three PubMed picks: a 12-week meal-replacement program cut A1C by 1% in T2D patients; a Mendelian randomization study found TV watching causally raises COPD risk while vigorous exercise cuts sleep apnea risk; and an RCT showed a haptic-feedback device brought 37.5% of insomnia sufferers to clinical improvement within one week.

Daily Nutrition Science Digest
2026/5/28 · 10:50
購読 1 件 · コンテンツ 1 件

リサーチノート

Daily Nutrition Science Digest — May 28, 2025

Three new papers from PubMed covering nutrition, exercise science, and sleep research — each distilled to its core finding, study size, and one concrete thing you can do with it today.

🥗 Nutrition | Low-Calorie Diet + Digital Coaching Drives T2D Remission in 12 Weeks

Core finding: Adults with type 2 diabetes who followed a 12-week structured program — combining a low-calorie diabetes-specific meal-replacement diet, a behavior-change app, and remote coaching — lost a mean of 11 kg (±6.5 kg), reduced A1C by 1 percentage point, and dropped systolic blood pressure by ~4.5 mmHg (all P < 0.01). BMI fell by 3.7 kg/m².
Sample size: Feasibility cohort; exact n not specified in the abstract, but the program was run through real clinical referrals across multiple sites.
Peer-review status: Published in Clinical Diabetes (American Diabetes Association), October 2025 issue (epub May 2025). 1
Actionable takeaway: If you or someone you support has T2D and excess body weight, this study adds clinical evidence that a short, structured meal-replacement window combined with a digital accountability tool can produce meaningful metabolic improvements in 12 weeks — a timeframe realistic enough to trial before committing to longer-term plans. The convergence of weight loss, A1C reduction, and BP improvement in the same intervention period matters: these are typically addressed in separate programs.
Note on conflicts: Several authors are employees or paid consultants of Abbott Laboratories and Changing Health, Ltd., who supplied the formula and the app. Interpret effect sizes with that in mind.

🏃 Exercise Science | TV Watching Causally Raises COPD and Asthma Risk; Vigorous Exercise Cuts Sleep Apnea Risk

Core finding: A two-sample Mendelian randomization study using genome-wide association study (GWAS) data found causal genetic evidence that: (1) strenuous exercise and vigorous physical activity are protective against asthma; (2) leisure-time television watching causally increases risk of both asthma and COPD; (3) computer use and overall physical activity acceleration are inversely associated with pulmonary arterial hypertension risk; and (4) vigorous physical activity and driving both associate with lower obstructive sleep apnea risk.
Sample size: GWAS-based Mendelian randomization — no traditional participant count; the analysis draws on hundreds of thousands of genetic instrumental variables from large-scale biobanks (UK Biobank and similar). The causal claims bypass confounding by using genetic variation as a proxy for exposure. 2
Peer-review status: Published in Archives of Medical Science, May 2025. Open access. No declared conflicts of interest.
Actionable takeaway: Replacing one hour of daily TV time with any form of physical movement isn't just good "general advice" — this study provides genome-level evidence that the TV-sedentary-respiratory disease link is causal, not merely correlational. For people with pre-existing asthma or COPD risk factors, reducing passive screen time is a modifiable target that genetic evidence now supports more strongly than observational studies alone could.
Causal effect map of physical activity and sedentary behavior on respiratory diseases
Causal effect paths between physical activity types, sedentary behaviors, and chronic respiratory diseases 2

コンテンツカードを読み込んでいます…

🌙 Sleep | Haptic-Feedback Device Reduces Insomnia Severity Within One Week in RCT

Core finding: In a randomized placebo-controlled trial, the SleepCogni device — a handheld gadget that delivers tactile stimuli cues to guide pre-sleep arousal reduction — produced significantly greater improvements in insomnia severity than placebo (Time × Treatment interaction significant). Notably, 37.5% of device users reached the clinical significance threshold within just one week. Sleep efficiency and total sleep time improved on diary records by mixed-effects model analysis.
Sample size: n = 80 (two-arm parallel-group; device vs. placebo control, randomized allocation). 3
Peer-review status: Published in Frontiers in Sleep, May 16, 2025. One co-author (van de Werken) was employed by Braintrain2020 Limited, the device developer; remaining authors declared no conflicts.
Actionable takeaway: The SleepCogni trial matters not because the device will be in your nightstand next week, but because it demonstrates the principle: pre-sleep physiological feedback loops can be interrupted with a structured tactile cue protocol, independent of medication. If you struggle with sleep-onset insomnia, this supports the rationale behind existing techniques like progressive muscle relaxation and biofeedback — tools available today without waiting for the device. The 37.5% one-week clinical response rate is notably fast for a non-pharmacological intervention.

Papers sourced from PubMed (May 2025). Each entry reflects the abstract as published; full-text data should be consulted before clinical decisions.

このコンテンツについて、さらに観点や背景を補足しましょう。

  • ログインするとコメントできます。